The Notice of Allowance covers the use of key compounds contained in the ingredients in Tollovid and Tollovir (NLC-V-01, NLC-001 or 3CL-001). The allowed claims are directed, among other things, to the administration of compounds to a subject to inhibit activity of the 3CL protease, inflammation and autophagy, and to treat coronavirus infection.
The USPTO's assessment pertains solely to patentability, while approvability as a disease treatment falls solely within the jurisdiction of the
Tollovid and Tollovir are manufactured with distinct raw materials, such that the key ingredients of Tollovir are separate and distinct from the key ingredients in Tollovid, resulting in separate end products from different key raw materials that contain patent pending compounds.
Dr.
'The USPTO granting of this Notice of Allowance marks a major milestone for the Tollovid and Tollovir programs,' said
About
Founded in
Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
Todos formed the Israeli-based majority-owned joint venture 3CL
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law,
Contact:
Email: gerald@todosmedical.com
(C) 2023 Electronic News Publishing, source